Allianz Asset Management GmbH Purchases 534,527 Shares of Qiagen N.V. $QGEN

Allianz Asset Management GmbH lifted its position in shares of Qiagen N.V. (NYSE:QGEN) by 53.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,529,224 shares of the company’s stock after acquiring an additional 534,527 shares during the period. Allianz Asset Management GmbH owned approximately 0.69% of Qiagen worth $68,028,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in QGEN. MAI Capital Management boosted its stake in Qiagen by 998.9% during the 2nd quarter. MAI Capital Management now owns 978 shares of the company’s stock valued at $47,000 after purchasing an additional 889 shares during the last quarter. Allworth Financial LP lifted its holdings in shares of Qiagen by 260.1% during the second quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock valued at $53,000 after purchasing an additional 796 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Qiagen by 375.5% during the third quarter. GAMMA Investing LLC now owns 1,241 shares of the company’s stock valued at $55,000 after buying an additional 980 shares during the last quarter. Cullen Frost Bankers Inc. boosted its position in shares of Qiagen by 13,144.4% during the second quarter. Cullen Frost Bankers Inc. now owns 1,192 shares of the company’s stock valued at $57,000 after buying an additional 1,183 shares during the last quarter. Finally, Jones Financial Companies Lllp increased its holdings in Qiagen by 64.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,610 shares of the company’s stock worth $71,000 after buying an additional 628 shares in the last quarter. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Qiagen

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Q4 results: EPS of $0.62 and revenue growth of ~3.6% YoY; the company showed solid margins (net margin ~19.6%) and return on equity (~14.8%), which support the earnings quality. View Press Release
• Positive Sentiment: Product/market expansion: Qiagen showcased QIAsprint Connect — a benchtop high-throughput automation system — at SLAS 2026, signaling entry into higher-volume sample?processing for research labs (potential long?term revenue upside). Article Title
• Positive Sentiment: Analyst sentiment: Several media/analyst write?ups highlighted Qiagen among favored healthcare names, which can provide continued analyst support for the shares. Article Title
• Neutral Sentiment: Street comparisons: Coverage summarizes how key Q4 metrics stack up to Wall Street — results are largely in line with expectations but show only modest year?over?year improvement. Article Title
• Negative Sentiment: Guidance miss: Management lowered near?term expectations — Q1 EPS guidance of ~$0.54 (consensus ~$0.60) and Q1 revenue guidance of ~$487.8M (consensus ~$511.8M); FY?2026 EPS guide of ~$2.50 vs. consensus ~$2.63, while FY revenue guidance is roughly in line. The below?consensus EPS and Q1 revenue outlook are the primary reasons the stock is under pressure. View Press Release

Qiagen Stock Performance

QGEN opened at $51.79 on Thursday. The company’s 50 day moving average is $49.62 and its 200 day moving average is $49.66. The company has a current ratio of 2.60, a quick ratio of 2.30 and a debt-to-equity ratio of 0.45. The company has a market cap of $10.94 billion, a price-to-earnings ratio of 26.74, a PEG ratio of 2.49 and a beta of 0.67. Qiagen N.V. has a 12-month low of $39.61 and a 12-month high of $57.81.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Wednesday, February 4th. The company reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.03. Qiagen had a net margin of 19.58% and a return on equity of 14.80%. During the same period in the prior year, the firm earned $0.61 EPS. The firm’s revenue was up 3.6% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. On average, equities research analysts predict that Qiagen N.V. will post 2.26 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on QGEN shares. UBS Group restated a “neutral” rating on shares of Qiagen in a research note on Wednesday, January 21st. Citigroup downgraded shares of Qiagen from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $57.89 to $52.63 in a research report on Thursday, December 11th. Weiss Ratings restated a “hold (c)” rating on shares of Qiagen in a report on Monday, December 29th. Wall Street Zen lowered shares of Qiagen from a “buy” rating to a “hold” rating in a research note on Saturday, January 10th. Finally, Deutsche Bank Aktiengesellschaft cut Qiagen from a “buy” rating to a “hold” rating and increased their price target for the company from $52.00 to $54.00 in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $53.04.

Qiagen Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library?preparation kits and proteomics solutions.